Stifel Resumes Senseonics Holdings (SENS) at Hold

Stifel analyst Jonathan Block resumes coverage on Senseonics Holdings (NYSE: SENS) with a Hold rating, PT $9.00.

The analyst comments "Overall, we view our physician diligence favorably. We identify increasing Eversense 365-day share gains across several segments of the T2 market and Gemini was in the impressive number three slot among CGM innovations. Most importantly, we view the recent news that Senseonics will soon take commercial operations back from Ascensia as positive. It puts commercial control in Senseonics’ hands, and they can better drive 365-day awareness, which is a significant barrier (page 26). However, this transition will likely require additional capital, and we feel the Freedom sensor (2H27) is the form factor that will matter most for physicians and patients. Resume coverage with a Hold rating."

For an analyst ratings summary and ratings history on Senseonics Holdings click here. For more ratings news on Senseonics Holdings click here.

Shares of Senseonics Holdings closed at $8.16 yesterday.

You May Also Be Interested In

• Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
• Guidewire (GWRE) PT Raised to $225 at Stifel
• Integra Resources (ITRG) Tops Q2 EPS by 6c